Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Critically Ill
Conditions
Critically Ill, Pneumonia
Trial Timeline
Feb 5, 2015 → Jun 16, 2017
NCT ID
NCT02387372About Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose
Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose is a phase 1 stage product being developed by Merck for Critically Ill. The current trial status is completed. This product is registered under clinical trial identifier NCT02387372. Target conditions include Critically Ill, Pneumonia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02387372 | Phase 1 | Completed |
Competing Products
1 competing product in Critically Ill
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 85 |